{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:53:50Z","timestamp":1793159630792,"version":"4.5.0"},"reference-count":260,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1162060"],"award-info":[{"award-number":["APP1162060"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.neuropharm.2021.108555","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T02:17:31Z","timestamp":1617934651000},"page":"108555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"special_numbering":"C","title":["The cannabinoid system and microglia in health and disease"],"prefix":"10.1016","volume":"190","author":[{"given":"Samuel S.","family":"Duffy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5849-3520","authenticated-orcid":false,"given":"Jessica P.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan T.","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3828-9527","authenticated-orcid":false,"given":"Gila","family":"Moalem-Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41593-018-0100-x","article-title":"Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models","volume":"21","author":"Ajami","year":"2018","journal-title":"Nat. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18040691","article-title":"(-)-\u03b2-Caryophyllene, a CB2 receptor-selective phytocannabinoid, suppresses motor paralysis and neuroinflammation in a murine model of multiple sclerosis","volume":"18","author":"Alberti","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1074\/jbc.M111.296020","article-title":"Modulation of L-\u03b1-lysophosphatidylinositol\/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids","volume":"287","author":"Anavi-Goffer","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2021.108555_bib4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3389\/fncel.2019.00424","article-title":"The endocannabinoid system as a window into microglial biology and its relationship to autism","volume":"13","author":"Araujo","year":"2019","journal-title":"Front. Cell. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib5","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1523\/JNEUROSCI.23-07-02511.2003","article-title":"Therapeutic action of cannabinoids in a murine model of multiple sclerosis","volume":"23","author":"Ar\u00e9valo-Mart\u00edn","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108555_bib6","doi-asserted-by":"crossref","first-page":"105923","DOI":"10.1016\/j.intimp.2019.105923","article-title":"Combination of Imipramine, a sphingomyelinase inhibitor, and \u03b2-caryophyllene improve their therapeutic effects on experimental autoimmune encephalomyelitis (EAE)","volume":"77","author":"Askari","year":"2019","journal-title":"Int. Immunopharm."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3233\/JAD-150913","article-title":"Cannabinoid receptor 2 participates in amyloid-\u03b2 processing in a mouse model of alzheimer's disease but plays a minor role in the therapeutic properties of a cannabis-based medicine","volume":"51","author":"Aso","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2021.108555_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jneuroim.2010.08.013","article-title":"The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines","volume":"229","author":"Austin","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nyas.13712","article-title":"Inflammation in psychiatric disorders: what comes first?","volume":"1437","author":"Bauer","year":"2019","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"11","key":"10.1016\/j.neuropharm.2021.108555_bib10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nri2190","article-title":"The origin and application of experimental autoimmune encephalomyelitis","volume":"7","author":"Baxter","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"35","key":"10.1016\/j.neuropharm.2021.108555_bib11","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","article-title":"Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains","volume":"23","author":"Benito","year":"2003","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108555_bib12","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1523\/JNEUROSCI.4814-06.2007","article-title":"Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis","volume":"27","author":"Benito","year":"2007","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1586\/ern.09.59","article-title":"Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy","volume":"9","author":"Bernstein","year":"2009","journal-title":"Expert Rev. Neurother."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/ACO.0000000000000616","article-title":"An overview of the cannabinoid type 2 receptor system and its therapeutic potential","volume":"31","author":"Bie","year":"2018","journal-title":"Curr. Opin. Anaesthesiol."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib15","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1096\/fj.05-4743fje","article-title":"Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice","volume":"20","author":"Bilsland","year":"2006","journal-title":"Faseb. J."},{"issue":"23","key":"10.1016\/j.neuropharm.2021.108555_bib16","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.2174\/138161208785740081","article-title":"The endocannabinoid system in amyotrophic lateral sclerosis","volume":"14","author":"Bilsland","year":"2008","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2021.108555_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neuropharm.2018.08.007","article-title":"Revisiting cannabinoid receptor 2 expression and function in murine retina","volume":"141","author":"Borowska-Fielding","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2021.108555_bib18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejphar.2012.02.008","article-title":"Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells","volume":"682","author":"Burgos","year":"2012","journal-title":"Eur. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.neuropharm.2021.108555_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080440","article-title":"Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint","volume":"8","author":"Burston","year":"2013","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nn.3599","article-title":"Identification of a unique TGF-beta-dependent molecular and functional signature in microglia","volume":"17","author":"Butovsky","year":"2014","journal-title":"Nat. Neurosci."},{"issue":"10","key":"10.1016\/j.neuropharm.2021.108555_bib21","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41583-018-0057-5","article-title":"Microglial signatures and their role in health and disease","volume":"19","author":"Butovsky","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108555_bib22","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1017\/S1462399409000957","article-title":"Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation","volume":"11","author":"Cabral","year":"2009","journal-title":"Expet Rev. Mol. Med."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib23","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1189\/jlb.0405216","article-title":"Cannabinoid receptors in microglia of the central nervous system: immune functional relevance","volume":"78","author":"Cabral","year":"2005","journal-title":"J. Leukoc. Biol."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib24","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1017\/S1461145712001502","article-title":"The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system","volume":"16","author":"Campos","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib25","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1124\/mol.65.4.999","article-title":"Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism","volume":"65","author":"Carrier","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094733","article-title":"A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis","volume":"9","author":"Carrillo-Salinas","year":"2014","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FBP.0b013e32833b33c5","article-title":"Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors","volume":"21","author":"Casarotto","year":"2010","journal-title":"Behav. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108555_bib28","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/mp.2014.14","article-title":"CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex","volume":"19","author":"Cass","year":"2014","journal-title":"Mol. Psychiatr."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib29","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.neuron.2018.11.009","article-title":"Microglia in pain: detrimental and protective roles in pathogenesis and resolution of pain","volume":"100","author":"Chen","year":"2018","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.celrep.2013.06.018","article-title":"A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model","volume":"4","author":"Chiu","year":"2013","journal-title":"Cell Rep."},{"issue":"17","key":"10.1016\/j.neuropharm.2021.108555_bib31","doi-asserted-by":"crossref","first-page":"7975","DOI":"10.1073\/pnas.0913449107","article-title":"Enhanced synaptic connectivity and epilepsy in C1q knockout mice","volume":"107","author":"Chu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108555_bib32","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.4049\/jimmunol.1102435","article-title":"Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation","volume":"187","author":"Chung","year":"2011","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2015.100","article-title":"CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease","volume":"48","author":"Chung","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.neuropharm.2021.108555_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.expneurol.2015.04.007","article-title":"Differential upregulation of the cannabinoid CB\u2082 receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease","volume":"269","author":"Concannon","year":"2015","journal-title":"Exp. Neurol."},{"issue":"Pt A","key":"10.1016\/j.neuropharm.2021.108555_bib35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.expneurol.2016.06.014","article-title":"Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease","volume":"283","author":"Concannon","year":"2016","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib36","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bbr.2009.12.044","article-title":"The history of the cholinergic hypothesis","volume":"221","author":"Contestabile","year":"2011","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib37","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bbi.2011.01.020","article-title":"The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70\/IL-23 axis and IL-10 in microglial cells","volume":"25","author":"Correa","year":"2011","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2021.108555_bib38","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3389\/fimmu.2017.00618","article-title":"Neuroimmune interactions in schizophrenia: focus on vagus nerve stimulation and activation of the alpha-7 nicotinic acetylcholine receptor","volume":"8","author":"Corsi-Zuelli","year":"2017","journal-title":"Front. Immunol."},{"issue":"6477","key":"10.1016\/j.neuropharm.2021.108555_bib39","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1126\/science.aax6752","article-title":"Microglia monitor and protect neuronal function through specialized somatic purinergic junctions","volume":"367","author":"Cserep","year":"2020","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib40","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.neuropharm.2012.01.030","article-title":"Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects","volume":"62","author":"de Lago","year":"2012","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol."},{"issue":"48","key":"10.1016\/j.neuropharm.2021.108555_bib42","doi-asserted-by":"crossref","first-page":"16091","DOI":"10.1523\/JNEUROSCI.2400-10.2010","article-title":"The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration","volume":"30","author":"Deleidi","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108555_bib43","series-title":"Anesthesia and Analgesia in Laboratory Animals","first-page":"3","article-title":"Chapter 1 - anatomy, physiology, and effects of pain","author":"DeMarco","year":"2008"},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108555_bib44","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib45","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.stem.2008.09.017","article-title":"Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation","volume":"3","author":"Di Giorgio","year":"2008","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108555_bib46","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nn1885","article-title":"Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model","volume":"10","author":"Di Giorgio","year":"2007","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrn3876","article-title":"Endocannabinoid signalling and the deteriorating brain","volume":"16","author":"Di Marzo","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2021.108555_bib48","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009258","article-title":"Parkinson's disease and parkinsonism: neuropathology","volume":"2","author":"Dickson","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.neuropharm.2021.108555_bib49","first-page":"285245","article-title":"The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"2014","author":"Duffy","year":"2014","journal-title":"Mult Scler Int"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/mds.25664","article-title":"Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms","volume":"29","author":"Duncan","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2021.108555_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1742-2094-2-29","article-title":"Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation","volume":"2","author":"Ehrhart","year":"2005","journal-title":"J. Neuroinflammation"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib52","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","article-title":"Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L","volume":"95","author":"El-Alfy","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00213-011-2566-z","article-title":"Anxiogenic-like effects of chronic cannabidiol administration in rats","volume":"221","author":"ElBatsh","year":"2012","journal-title":"Psychopharmacology (Berlin)"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neuron.2005.11.027","article-title":"The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells","volume":"49","author":"Eljaschewitsch","year":"2006","journal-title":"Neuron"},{"issue":"10","key":"10.1016\/j.neuropharm.2021.108555_bib55","first-page":"1585","article-title":"Targeting glial cannabinoid CB","volume":"176","author":"Espejo-Porras","year":"2019","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11481-015-9602-4","article-title":"Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders","volume":"10","author":"Espejo-Porras","year":"2015","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib57","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1124\/jpet.107.121566","article-title":"Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence","volume":"322","author":"Esposito","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib58","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.neuropharm.2012.05.013","article-title":"WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-\u03b3 pathway","volume":"63","author":"Fakhfouri","year":"2012","journal-title":"Neuropharmacology"},{"issue":"26","key":"10.1016\/j.neuropharm.2021.108555_bib59","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.1523\/JNEUROSCI.1146-14.2014","article-title":"IL-4 signaling drives a unique arginase+\/IL-1beta+ microglia phenotype and recruits macrophages to the inflammatory CNS: consequences of age-related deficits in IL-4Ralpha after traumatic spinal cord injury","volume":"34","author":"Fenn","year":"2014","journal-title":"J. Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2021.108555_bib60","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.neurobiolaging.2014.05.021","article-title":"Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model","volume":"35","author":"Fern\u00e1ndez-Su\u00e1rez","year":"2014","journal-title":"Neurobiol. Aging"},{"issue":"11","key":"10.1016\/j.neuropharm.2021.108555_bib61","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrneurol.2011.152","article-title":"Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis","volume":"7","author":"Ferraiuolo","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib62","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1089\/ars.2009.2444","article-title":"Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis","volume":"11","author":"Foran","year":"2009","journal-title":"Antioxidants Redox Signal."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108555_bib63","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.neuron.2014.01.013","article-title":"Microglia induce motor neuron death via the classical NF-\u03baB pathway in amyotrophic lateral sclerosis","volume":"81","author":"Frakes","year":"2014","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108555_bib64","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/glia.23694","article-title":"Potentiation of cannabinoid signaling in microglia by adenosine A2A receptor antagonists","volume":"67","author":"Franco","year":"2019","journal-title":"Glia"},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108555_bib65","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/glia.23694","article-title":"Potentiation of cannabinoid signaling in microglia by adenosine A","volume":"67","author":"Franco","year":"2019","journal-title":"Glia"},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2021.108555_bib66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(03)02074-0","article-title":"Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors","volume":"474","author":"Franklin","year":"2003","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2021.108555_bib67","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tcb.2016.02.006","article-title":"Microglia: architects of the developing nervous system","volume":"26","author":"Frost","year":"2016","journal-title":"Trends Cell Biol."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib68","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S1461145709990617","article-title":"Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol","volume":"13","author":"Fusar-Poli","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","article-title":"Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing","volume":"66","author":"Fusar-Poli","year":"2009","journal-title":"Arch. Gen. Psychiatr."},{"issue":"30","key":"10.1016\/j.neuropharm.2021.108555_bib70","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1523\/JNEUROSCI.0143-07.2008","article-title":"Neuroinflammation and oxidation\/nitration of alpha-synuclein linked to dopaminergic neurodegeneration","volume":"28","author":"Gao","year":"2008","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib71","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1476-5381.2011.01278.x","article-title":"Symptom-relieving and neuroprotective effects of the phytocannabinoid \u0394\u2079-THCV in animal models of Parkinson's disease","volume":"163","author":"Garc\u00eda","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib72","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Garc\u00eda-Arencibia","year":"2007","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib73","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/0269881110379507","article-title":"Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice","volume":"25","author":"Garc\u00eda-Guti\u00e9rrez","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib74","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s13311-018-0610-y","article-title":"Alterations in gene and protein expression of cannabinoid CB(2) and GPR55 receptors in the dorsolateral prefrontal cortex of suicide victims","volume":"15","author":"Garc\u00eda-Guti\u00e9rrez","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib75","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/j.1476-5381.2010.00819.x","article-title":"Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors","volume":"160","author":"Garc\u00eda-Guti\u00e9rrez","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib76","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13024-019-0335-3","article-title":"Microglia affect alpha-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease","volume":"14","author":"George","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"6005","key":"10.1016\/j.neuropharm.2021.108555_bib77","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1194637","article-title":"Fate mapping analysis reveals that adult microglia derive from primitive macrophages","volume":"330","author":"Ginhoux","year":"2010","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib78","first-page":"175","article-title":"Multiple sclerosis review","volume":"37","author":"Goldenberg","year":"2012","journal-title":"P T"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib79","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu018","article-title":"Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia","volume":"18","author":"Gomes","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108555_bib80","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu041","article-title":"Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice","volume":"18","author":"Gomes","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2021.108555_bib81","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.schres.2015.01.015","article-title":"Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol","volume":"164","author":"Gomes","year":"2015","journal-title":"Schizophr. Res."},{"issue":"6344","key":"10.1016\/j.neuropharm.2021.108555_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal3222","article-title":"An environment-dependent transcriptional network specifies human microglia identity","volume":"356","author":"Gosselin","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib83","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s11481-012-9399-3","article-title":"A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis","volume":"7","author":"Granja","year":"2012","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108555_bib84","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pnpbp.2015.03.017","article-title":"Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease","volume":"64","author":"G\u00f3mez-G\u00e1lvez","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib85","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1517\/14728214.2011.604312","article-title":"Emerging drugs for amyotrophic lateral sclerosis","volume":"16","author":"Habib","year":"2011","journal-title":"Expet Opin. Emerg. Drugs"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib86","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1213\/ANE.0000000000004033","article-title":"Microglial modulation as a target for chronic pain: from the bench to the bedside and back","volume":"128","author":"Haight","year":"2019","journal-title":"Anesth. Analg."},{"issue":"11","key":"10.1016\/j.neuropharm.2021.108555_bib87","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrneurol.2011.153","article-title":"Clinical diagnosis and management of amyotrophic lateral sclerosis","volume":"7","author":"Hardiman","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib88","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1476-5381.2009.00625.x","article-title":"GPR55 ligands promote receptor coupling to multiple signalling pathways","volume":"160","author":"Henstridge","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108555_bib89","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/nn.3554","article-title":"The microglial sensome revealed by direct RNA sequencing","volume":"16","author":"Hickman","year":"2013","journal-title":"Nat. Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib90","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/187152709789824624","article-title":"The endocannabinoid system and the treatment of mood and anxiety disorders","volume":"8","author":"Hill","year":"2009","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2021.108555_bib91","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1016\/S1353-8020(11)70065-7","article-title":"Neuroinflammation in Parkinson's disease","volume":"18","author":"Hirsch","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2021.108555_bib92","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40478-015-0203-5","article-title":"Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis","volume":"3","author":"Holtman","year":"2015","journal-title":"Acta Neuropathol Commun"},{"issue":"14","key":"10.1016\/j.neuropharm.2021.108555_bib93","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1016\/j.bmc.2010.05.058","article-title":"Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2)","volume":"18","author":"Horti","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib94","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0026-895X(25)10219-8","article-title":"Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs","volume":"29","author":"Howlett","year":"1986","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib95","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrneurol.2014.207","article-title":"Microglial and macrophage polarization-new prospects for brain repair","volume":"11","author":"Hu","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib96","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nrn.2018.2","article-title":"Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential","volume":"19","author":"Inoue","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108555_bib97","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fnins.2016.00321","article-title":"Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson's disease","volume":"10","author":"Javed","year":"2016","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib98","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/j.pain.0000000000000470","article-title":"High-resolution transcriptome analysis reveals neuropathic pain gene-expression signatures in spinal microglia after nerve injury","volume":"157","author":"Jeong","year":"2016","journal-title":"Pain"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2021.108555_bib99","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.pain.2013.06.022","article-title":"Glia and pain: is chronic pain a gliopathy?","volume":"154","author":"Ji","year":"2013","journal-title":"Pain"},{"issue":"14","key":"10.1016\/j.neuropharm.2021.108555_bib100","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1073\/pnas.1017033108","article-title":"Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration","volume":"108","author":"Jin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.neuropharm.2021.108555_bib101","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1523\/JNEUROSCI.23-10-04017.2003","article-title":"p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain","volume":"23","author":"Jin","year":"2003","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108555_bib102","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1007\/s00415-006-0195-y","article-title":"Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London","volume":"253","author":"Johnston","year":"2006","journal-title":"J. Neurol."},{"issue":"9996","key":"10.1016\/j.neuropharm.2021.108555_bib103","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2021.108555_bib104","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejphar.2016.06.039","article-title":"Pattern recognition receptors in chronic pain: mechanisms and therapeutic implications","volume":"788","author":"Kato","year":"2016","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib105","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","article-title":"A unique microglia type Associated with restricting development of alzheimer's disease","volume":"169","author":"Keren-Shaul","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib106","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1152\/physrev.00011.2010","article-title":"Physiology of microglia","volume":"91","author":"Kettenmann","year":"2011","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib107","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nn.3318","article-title":"Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways","volume":"16","author":"Kierdorf","year":"2013","journal-title":"Nat. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2021.108555_bib108","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejphar.2006.05.025","article-title":"AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis","volume":"542","author":"Kim","year":"2006","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2013.11.002","article-title":"Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS","volume":"287","author":"Kong","year":"2014","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.neuropharm.2021.108555_bib110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2119\/molmed.2013.00140.revised","article-title":"CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease","volume":"20","author":"Koppel","year":"2014","journal-title":"Mol. Med."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib111","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1476-5381.2011.01379.x","article-title":"Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL\/6 mice","volume":"163","author":"Kozela","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib112","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","article-title":"The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases","volume":"47","author":"Krasemann","year":"2017","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.neuropharm.2021.108555_bib113","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0166-2236(96)10049-7","article-title":"Microglia: a sensor for pathological events in the CNS","volume":"19","author":"Kreutzberg","year":"1996","journal-title":"Trends Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108555_bib114","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.phrs.2007.09.006","article-title":"The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction","volume":"56","author":"Lafen\u00eatre","year":"2007","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib115","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.0711278105","article-title":"GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current","volume":"105","author":"Lauckner","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2021.108555_bib116","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fnmol.2016.00089","article-title":"Protective microglia and their regulation in Parkinson's disease","volume":"9","author":"Le","year":"2016","journal-title":"Front. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib117","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4049\/jimmunol.0903480","article-title":"Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1","volume":"185","author":"Lee","year":"2010","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib118","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2021.108555_bib119","doi-asserted-by":"crossref","first-page":"134286","DOI":"10.1016\/j.neulet.2019.134286","article-title":"CB2 cannabinoid receptor agonist ameliorates novel object recognition but not spatial memory in transgenic APP\/PS1 mice","volume":"707","author":"Li","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2021.108555_bib120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fneur.2016.00005","article-title":"Microglial cells as a link between cannabinoids and the immune hypothesis of psychiatric disorders","volume":"7","author":"Lisboa","year":"2016","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108555_bib121","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/s41386-018-0064-2","article-title":"Repeated social defeat-induced neuroinflammation, anxiety-like behavior and resistance to fear extinction were attenuated by the cannabinoid receptor agonist WIN55,212-2","volume":"43","author":"Lisboa","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib122","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1523\/JNEUROSCI.2235-16.2016","article-title":"TNF-\u03b1 differentially regulates synaptic plasticity in the Hippocampus and spinal cord by microglia-dependent mechanisms after peripheral nerve injury","volume":"37","author":"Liu","year":"2017","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib123","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/bph.12519","article-title":"Sex-dependent long-term effects of adolescent exposure to THC and\/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats","volume":"171","author":"Lopez-Rodriguez","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108555_bib124","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jneuroim.2018.02.001","article-title":"The inhibition of CB","volume":"317","author":"Lou","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuropharm.2021.108555_bib125","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.brainres.2011.03.020","article-title":"Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis","volume":"1390","author":"Lourbopoulos","year":"2011","journal-title":"Brain Res."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib126","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biol. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib127","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1871527311312010009","article-title":"Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial\/microglial phenotypical changes in mice","volume":"12","author":"Luongo","year":"2013","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.nbd.2009.09.021","article-title":"1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice","volume":"37","author":"Luongo","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib129","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12974-018-1174-9","article-title":"Cannabinoid CB","volume":"15","author":"L\u00f3pez","year":"2018","journal-title":"J. Neuroinflammation"},{"issue":"11","key":"10.1016\/j.neuropharm.2021.108555_bib130","first-page":"1251","article-title":"[Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia]","volume":"24","author":"L\u00fc","year":"2004","journal-title":"Di Yi Jun Yi Da Xue Xue Bao"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib131","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bbrc.2015.01.073","article-title":"Activation of murine microglial N9 cells is attenuated through cannabinoid receptor CB2 signaling","volume":"458","author":"Ma","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108555_bib132","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1073\/pnas.89.9.3825","article-title":"Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells","volume":"89","author":"Mackie","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2021.108555_bib133","first-page":"130639","article-title":"Anandamide, acting via CB2 receptors, alleviates LPS-induced neuroinflammation in rat primary microglial cultures","author":"Malek","year":"2015","journal-title":"Neural Plast."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108555_bib134","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.phrs.2007.09.003","article-title":"Enhancement of endocannabinoid signaling and the pharmacotherapy of depression","volume":"56","author":"Mangieri","year":"2007","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2021.108555_bib135","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bcp.2018.07.042","article-title":"Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination","volume":"157","author":"Manterola","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib136","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1124\/mol.111.071290","article-title":"Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease","volume":"79","author":"Mart\u00edn-Moreno","year":"2011","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib137","doi-asserted-by":"crossref","first-page":"a006262","DOI":"10.1101\/cshperspect.a006262","article-title":"Biochemistry of amyloid \u03b2-protein and amyloid deposits in Alzheimer disease","volume":"2","author":"Masters","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7744","key":"10.1016\/j.neuropharm.2021.108555_bib138","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41586-019-0924-x","article-title":"Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution","volume":"566","author":"Masuda","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108555_bib139","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.celrep.2020.01.010","article-title":"Microglia heterogeneity in the single-cell era","volume":"30","author":"Masuda","year":"2020","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.celrep.2017.09.039","article-title":"Temporal tracking of microglia activation in neurodegeneration at single-cell resolution","volume":"21","author":"Mathys","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2021.108555_bib141","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jneuroim.2017.07.007","article-title":"Time-course of striatal Toll-like receptor expression in neurotoxic, environmental and inflammatory rat models of Parkinson's disease","volume":"310","author":"McCabe","year":"2017","journal-title":"J. Neuroimmunol."},{"issue":"20","key":"10.1016\/j.neuropharm.2021.108555_bib142","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1002\/j.1460-2075.1996.tb00949.x","article-title":"Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities","volume":"15","author":"McKercher","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.neuropharm.2021.108555_bib143","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pharmthera.2016.06.011","article-title":"Microglia activation states and cannabinoid system: therapeutic implications","volume":"166","author":"Mecha","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2021.108555_bib144","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbi.2015.06.002","article-title":"Endocannabinoids drive the acquisition of an alternative phenotype in microglia","volume":"49","author":"Mecha","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2021.108555_bib145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.nbd.2013.06.016","article-title":"Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors","volume":"59","author":"Mecha","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib146","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/glia.23317","article-title":"2-AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs","volume":"66","author":"Mecha","year":"2018","journal-title":"Glia"},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib147","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1471-4159.2004.02979.x","article-title":"Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis","volume":"92","author":"Mestre","year":"2005","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib148","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.pnpbp.2006.08.013","article-title":"Possible antipsychotic effects of minocycline in patients with schizophrenia","volume":"31","author":"Miyaoka","year":"2007","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108555_bib149","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/WNF.0b013e3181593d45","article-title":"Minocycline as adjunctive therapy for schizophrenia: an open-label study","volume":"31","author":"Miyaoka","year":"2008","journal-title":"Clin. Neuropharmacol."},{"issue":"72","key":"10.1016\/j.neuropharm.2021.108555_bib150","first-page":"269","article-title":"The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view","volume":"Suppl","author":"Mi\u00fcller","year":"2007","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2021.108555_bib151","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejmech.2019.05.080","article-title":"Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment","volume":"178","author":"Montanari","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib152","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","article-title":"Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression","volume":"23","author":"Moreira","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108555_bib153","doi-asserted-by":"crossref","DOI":"10.3390\/biom10091228","article-title":"Gene expression analysis of astrocyte and microglia endocannabinoid signaling during autoimmune demyelination","volume":"10","author":"Moreno-Garc\u00eda","year":"2020","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib154","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.immuni.2018.02.014","article-title":"High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease","volume":"48","author":"Mrdjen","year":"2018","journal-title":"Immunity"},{"issue":"6441","key":"10.1016\/j.neuropharm.2021.108555_bib155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2021.108555_bib156","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1742-2094-9-79","article-title":"The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation","volume":"9","author":"Murphy","year":"2012","journal-title":"J. Neuroinflammation"},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib157","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1586\/14737175.8.7.1037","article-title":"Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia","volume":"8","author":"M\u00fcller-Vahl","year":"2008","journal-title":"Expert Rev. Neurother."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib158","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/oxfordjournals.jbchem.a002969","article-title":"Microglia: activation and their significance in the central nervous system","volume":"130","author":"Nakajima","year":"2001","journal-title":"J. Biochem."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib159","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12974-018-1103-y","article-title":"Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy","volume":"15","author":"Navarrete","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2021.108555_bib160","doi-asserted-by":"crossref","first-page":"104994","DOI":"10.1016\/j.nbd.2020.104994","article-title":"Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis","volume":"143","author":"Navarrete","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2021.108555_bib161","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbi.2017.08.015","article-title":"Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia","volume":"67","author":"Navarro","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2021.108555_bib162","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbi.2017.08.015","article-title":"Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB","volume":"67","author":"Navarro","year":"2018","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib163","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/s41598-019-43858-4","article-title":"CB2 receptor deletion on myeloid cells enhanced mechanical allodynia in a mouse model of neuropathic pain","volume":"9","author":"Nent","year":"2019","journal-title":"Sci. Rep."},{"issue":"5726","key":"10.1016\/j.neuropharm.2021.108555_bib164","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1126\/science.1110647","article-title":"Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo","volume":"308","author":"Nimmerjahn","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib165","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12974-017-0960-0","article-title":"Activation of dorsal horn cannabinoid CB2 receptor suppresses the expression of P2Y","volume":"14","author":"Niu","year":"2017","journal-title":"J. Neuroinflammation"},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib166","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ana.23687","article-title":"Meta-analysis of early nonmotor features and risk factors for Parkinson disease","volume":"72","author":"Noyce","year":"2012","journal-title":"Ann. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2021.108555_bib167","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11010-016-2733-y","article-title":"\u03b2-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease","volume":"418","author":"Ojha","year":"2016","journal-title":"Mol. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib168","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.bbrc.2007.08.078","article-title":"Identification of GPR55 as a lysophosphatidylinositol receptor","volume":"362","author":"Oka","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib169","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41467-018-02926-5","article-title":"A transcriptomic atlas of aged human microglia","volume":"9","author":"Olah","year":"2018","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib170","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/npp.2011.34","article-title":"Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice","volume":"36","author":"Ortega-Alvaro","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.neuropharm.2021.108555_bib171","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1096\/fj.04-2464fje","article-title":"Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis","volume":"19","author":"Ortega-Guti\u00e9rrez","year":"2005","journal-title":"Faseb. J."},{"issue":"16","key":"10.1016\/j.neuropharm.2021.108555_bib172","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201798697","article-title":"NF-\u03baB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS","volume":"37","author":"Ouali Alami","year":"2018","journal-title":"EMBO J."},{"issue":"Pt 11","key":"10.1016\/j.neuropharm.2021.108555_bib173","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib174","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13643-018-0934-z","article-title":"Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review","volume":"8","author":"Passavanti","year":"2019","journal-title":"Syst. Rev."},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108555_bib175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024034","article-title":"Cannabinoid agonists inhibit neuropathic pain induced by brachial plexus avulsion in mice by affecting glial cells and MAP kinases","volume":"6","author":"Paszcuk","year":"2011","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib176","first-page":"177","article-title":"Modulation of microglia phenotype","volume":"20","author":"Perry","year":"1994","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"11","key":"10.1016\/j.neuropharm.2021.108555_bib177","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/j.1460-9568.2009.06764.x","article-title":"WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"29","author":"Price","year":"2009","journal-title":"Eur. J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib178","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: a systematic review and metaanalysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"10","key":"10.1016\/j.neuropharm.2021.108555_bib179","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/nn.2923","article-title":"Heterogeneity of CNS myeloid cells and their roles in neurodegeneration","volume":"14","author":"Prinz","year":"2011","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib180","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1098-1136(20000101)29:1<58::AID-GLIA6>3.0.CO;2-W","article-title":"Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells","volume":"29","author":"Puffenbarger","year":"2000","journal-title":"Glia"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib181","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer's disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"46","key":"10.1016\/j.neuropharm.2021.108555_bib182","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1523\/JNEUROSCI.3400-08.2008","article-title":"Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain","volume":"28","author":"Racz","year":"2008","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib183","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1124\/jpet.103.052407","article-title":"Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy","volume":"306","author":"Raghavendra","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108555_bib184","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neuroscience.2015.01.030","article-title":"Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL\/6 mice","volume":"290","author":"Rahimi","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2021.108555_bib185","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1744-8069-10-27","article-title":"Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery","volume":"10","author":"Rahn","year":"2014","journal-title":"Mol. Pain"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib186","first-page":"33","article-title":"Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid","volume":"5","author":"Raman","year":"2004","journal-title":"Amyotroph Lateral Scler."},{"issue":"8","key":"10.1016\/j.neuropharm.2021.108555_bib187","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ram\u00edrez","year":"2005","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib188","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nn.3584","article-title":"State of play in amyotrophic lateral sclerosis genetics","volume":"17","author":"Renton","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108555_bib189","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bcp.2018.06.001","article-title":"Molecular and functional interaction between GPR18 and cannabinoid CB2 G-protein-coupled receptors. Relevance in neurodegenerative diseases","volume":"157","author":"Reyes-Resina","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11481-008-9100-z","article-title":"Nitrated alpha-synuclein and microglial neuroregulatory activities","volume":"3","author":"Reynolds","year":"2008","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108555_bib191","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.neuroscience.2013.09.005","article-title":"Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis","volume":"254","author":"Ribeiro","year":"2013","journal-title":"Neuroscience"},{"issue":"8","key":"10.1016\/j.neuropharm.2021.108555_bib192","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3390\/ph3082517","article-title":"Brain CB\u2082 receptors: implications for neuropsychiatric disorders","volume":"3","author":"Roche","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib193","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/bph.12283","article-title":"Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias","volume":"171","author":"Rodr\u00edguez-Cueto","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108555_bib194","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1742-2094-8-44","article-title":"Expression of mutant alpha-synuclein modulates microglial phenotype in vitro","volume":"8","author":"Rojanathammanee","year":"2011","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib195","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3121\/cmr.1.1.57","article-title":"Multiple sclerosis: it's not the disease you thought it was","volume":"1","author":"Rolak","year":"2003","journal-title":"Clin. Med. Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib196","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/ALN.0b013e318167af74","article-title":"Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury","volume":"108","author":"Romero-Sandoval","year":"2008","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib197","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.cell.2017.10.011","article-title":"Edaravone: a new drug approved for ALS","volume":"171","author":"Rothstein","year":"2017","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib198","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108555_bib199","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1601-5215.2011.00579.x","article-title":"Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala","volume":"23","author":"R\u00e9us","year":"2011","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.neuropharm.2021.108555_bib200","first-page":"68","article-title":"El tercer elemento de los centros nerviosos I. La microgl\u00eda en estado normal","volume":"9","author":"R\u00edo-Hortega","year":"1919","journal-title":"Bolet\u00edn de la Sociedad Espa\u00f1ola de Biolog\u00eda"},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib201","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129618","article-title":"Cannabinoid CB2 receptors in a mouse model of A\u03b2 amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation","volume":"10","author":"Savonenko","year":"2015","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108555_bib202","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.pain.2014.05.031","article-title":"Suppression of bone marrow-derived microglia in the amygdala improves anxiety-like behavior induced by chronic partial sciatic nerve ligation in mice","volume":"155","author":"Sawada","year":"2014","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib203","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.neurobiolaging.2014.09.019","article-title":"Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer's disease mouse model","volume":"36","author":"Schm\u00f6le","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib204","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3233\/JAD-180230","article-title":"Cannabinoid receptor 2-deficiency ameliorates disease symptoms in a mouse model with alzheimer's disease-like pathology","volume":"64","author":"Schm\u00f6le","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib205","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/j.pain.0000000000001365","article-title":"The IASP classification of chronic pain for ICD-11: chronic neuropathic pain","volume":"160","author":"Scholz","year":"2019","journal-title":"Pain"},{"issue":"6077","key":"10.1016\/j.neuropharm.2021.108555_bib206","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.1219179","article-title":"A lineage of myeloid cells independent of Myb and hematopoietic stem cells","volume":"336","author":"Schulz","year":"2012","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib207","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0304-3940(03)00172-1","article-title":"Selective microglial activation in the rat rotenone model of Parkinson's disease","volume":"341","author":"Sherer","year":"2003","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib208","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/AAP.0000000000000601","article-title":"Continuous intrathecal infusion of cannabinoid receptor agonists attenuates nerve ligation-induced pain in rats","volume":"42","author":"Shiue","year":"2017","journal-title":"Reg. Anesth. Pain Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib209","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1471-4159.2006.04346.x","article-title":"The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset","volume":"101","author":"Shoemaker","year":"2007","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib210","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S2215-0366(14)70307-4","article-title":"Young adult sequelae of adolescent cannabis use: an integrative analysis","volume":"1","author":"Silins","year":"2014","journal-title":"Lancet Psychiatr."},{"issue":"10","key":"10.1016\/j.neuropharm.2021.108555_bib211","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164094","article-title":"Assessment of the effects of MPTP and paraquat on dopaminergic neurons and microglia in the substantia nigra pars compacta of C57BL\/6 mice","volume":"11","author":"Smeyne","year":"2016","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib212","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.neurobiolaging.2012.06.005","article-title":"CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients","volume":"34","author":"Solas","year":"2013","journal-title":"Neurobiol. Aging"},{"issue":"6645","key":"10.1016\/j.neuropharm.2021.108555_bib213","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib214","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ana.20913","article-title":"How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis","volume":"60","author":"Steinman","year":"2006","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108555_bib215","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/glia.20983","article-title":"Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas","volume":"58","author":"Stella","year":"2010","journal-title":"Glia"},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib216","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0301-0082(98)00083-5","article-title":"The role of microglia and macrophages in the pathophysiology of the CNS","volume":"58","author":"Stoll","year":"1999","journal-title":"Prog. Neurobiol."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2021.108555_bib217","first-page":"64","article-title":"New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model of monoarthritis","volume":"129","author":"Sun","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2021.108555_bib218","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bbi.2014.01.018","article-title":"Immune system: a possible nexus between cannabinoids and psychosis","volume":"40","author":"Su\u00e1rez-Pinilla","year":"2014","journal-title":"Brain Behav. Immun."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2021.108555_bib219","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jnc.13691","article-title":"The clinical symptoms of Parkinson's disease","volume":"139","author":"Sveinbjornsdottir","year":"2016","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib220","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2174\/1570159X16666180702144644","article-title":"Modulation of the cannabinoid system: a new perspective for the treatment of the alzheimer's disease","volume":"17","author":"Talarico","year":"2019","journal-title":"Curr. Neuropharmacol."},{"issue":"22","key":"10.1016\/j.neuropharm.2021.108555_bib221","doi-asserted-by":"crossref","first-page":"8442","DOI":"10.1523\/JNEUROSCI.4036-14.2015","article-title":"Microglia disrupt mesolimbic reward circuitry in chronic pain","volume":"35","author":"Taylor","year":"2015","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib222","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.neurobiolaging.2010.09.012","article-title":"Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine","volume":"33","author":"Ternianov","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2021.108555_bib223","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brainres.2009.05.098","article-title":"The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages","volume":"1283","author":"Tolon","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2021.108555_bib224","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1744-8069-6-16","article-title":"Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain","volume":"6","author":"Toth","year":"2010","journal-title":"Mol. Pain"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib225","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1212\/CPJ.0b013e3182a1b8ab","article-title":"Prognosis and epidemiology of amyotrophic lateral sclerosis: analysis of a clinic population, 1997-2011","volume":"3","author":"Traxinger","year":"2013","journal-title":"Neurol Clin Pract"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib226","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/j.pain.0000000000001384","article-title":"Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11)","volume":"160","author":"Treede","year":"2019","journal-title":"Pain"},{"issue":"45","key":"10.1016\/j.neuropharm.2021.108555_bib227","doi-asserted-by":"crossref","first-page":"16064","DOI":"10.1523\/JNEUROSCI.4158-11.2011","article-title":"The role of microglia in the healthy brain","volume":"31","author":"Tremblay","year":"2011","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108555_bib228","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tins.2004.12.002","article-title":"Neuropathic pain and spinal microglia: a big problem from molecules in \"small\" glia","volume":"28","author":"Tsuda","year":"2005","journal-title":"Trends Neurosci."},{"issue":"6950","key":"10.1016\/j.neuropharm.2021.108555_bib229","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nature01786","article-title":"P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury","volume":"424","author":"Tsuda","year":"2003","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib230","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.imbio.2008.11.009","article-title":"Alternative activation of macrophages: immune function and cellular biology","volume":"214","author":"Varin","year":"2009","journal-title":"Immunobiology"},{"issue":"14","key":"10.1016\/j.neuropharm.2021.108555_bib231","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1523\/JNEUROSCI.0786-09.2009","article-title":"Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K\/Akt pathway","volume":"29","author":"Viscomi","year":"2009","journal-title":"J. Neurosci."},{"issue":"13","key":"10.1016\/j.neuropharm.2021.108555_bib232","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1523\/JNEUROSCI.4363-08.2009","article-title":"Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals","volume":"29","author":"Wake","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108555_bib233","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.neuroscience.2010.12.005","article-title":"Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat","volume":"175","author":"Walsh","year":"2011","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib234","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1523\/JNEUROSCI.23-04-01398.2003","article-title":"Nonpsychotropic cannabinoid receptors regulate microglial cell migration","volume":"23","author":"Walter","year":"2003","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.neuropharm.2021.108555_bib235","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/rapm-2019-101262","article-title":"Spinal cannabinoid receptor 2 activation reduces hypersensitivity associated with bone cancer pain and improves the integrity of the blood-spinal cord barrier","volume":"45","author":"Wang","year":"2020","journal-title":"Reg. Anesth. Pain Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib236","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12974-017-1045-9","article-title":"WWL70 protects against chronic constriction injury-induced neuropathic pain in mice by cannabinoid receptor-independent mechanisms","volume":"15","author":"Wen","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2021.108555_bib237","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neuropharm.2015.07.010","article-title":"Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis","volume":"99","author":"Wen","year":"2015","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib238","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00001756-200504250-00001","article-title":"Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis","volume":"16","author":"Weydt","year":"2005","journal-title":"Neuroreport"},{"issue":"38","key":"10.1016\/j.neuropharm.2021.108555_bib239","doi-asserted-by":"crossref","first-page":"16511","DOI":"10.1073\/pnas.0902743106","article-title":"The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo","volume":"106","author":"Whyte","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"16","key":"10.1016\/j.neuropharm.2021.108555_bib240","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1073\/pnas.0510418103","article-title":"Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection","volume":"103","author":"Witting","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.neuropharm.2021.108555_bib241","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1172\/JCI45178","article-title":"What is this thing called pain?","volume":"120","author":"Woolf","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108555_bib242","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1523\/JNEUROSCI.22-05-01763.2002","article-title":"Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease","volume":"22","author":"Wu","year":"2002","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108555_bib243","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neurobiolaging.2012.06.011","article-title":"Activation of the CB2 receptor system reverses amyloid-induced memory deficiency","volume":"34","author":"Wu","year":"2013","journal-title":"Neurobiol. Aging"},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108555_bib244","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jpain.2018.10.007","article-title":"Cannabinoid type 2 receptor system modulates paclitaxel-induced microglial dysregulation and central sensitization in rats","volume":"20","author":"Wu","year":"2019","journal-title":"J. Pain"},{"key":"10.1016\/j.neuropharm.2021.108555_bib245","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2017.05.044","article-title":"Activation of CB","volume":"811","author":"Wu","year":"2017","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib246","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1111\/j.1471-4159.2007.04677.x","article-title":"Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia","volume":"102","author":"Xiao","year":"2007","journal-title":"J. Neurochem."},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108555_bib247","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1111\/ejn.13414","article-title":"Activation of cannabinoid receptor 2 attenuates mechanical allodynia and neuroinflammatory responses in a chronic post-ischemic pain model of complex regional pain syndrome type I in rats","volume":"44","author":"Xu","year":"2016","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108555_bib248","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neulet.2018.10.017","article-title":"Activation of spinal macrophage-inducible C-type lectin induces mechanical allodynia and microglial activation in rats","volume":"690","author":"Yang","year":"2019","journal-title":"Neurosci. Lett."},{"issue":"9996","key":"10.1016\/j.neuropharm.2021.108555_bib249","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(15)00041-0","article-title":"Pain in the USA: states of suffering","volume":"386","author":"Yaqub","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2021.108555_bib250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2377-6-12","article-title":"COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord","volume":"6","author":"Yiangou","year":"2006","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108555_bib251","first-page":"795","article-title":"Clinical perspectives on autoimmune processes in schizophrenia","volume":"32","author":"Yum","year":"2009","journal-title":"Psychiatr. Clin."},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108555_bib252","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/j.euroneuro.2015.09.021","article-title":"Cortical neuroinflammation contributes to long-term cognitive dysfunctions following adolescent delta-9-tetrahydrocannabinol treatment in female rats","volume":"25","author":"Zamberletti","year":"2015","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108555_bib253","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108555_bib254","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1750-3639.2011.00477.x","article-title":"Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D--evidence for altered expression in multiple sclerosis","volume":"21","author":"Zhang","year":"2011","journal-title":"Brain Pathol."},{"issue":"12","key":"10.1016\/j.neuropharm.2021.108555_bib255","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1046\/j.1460-9568.2003.02704.x","article-title":"Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models","volume":"17","author":"Zhang","year":"2003","journal-title":"Eur. J. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108555_bib256","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.jcbfm.9600447","article-title":"Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia\/reperfusion model","volume":"27","author":"Zhang","year":"2007","journal-title":"J. Cerebr. Blood Flow Metabol."},{"issue":"11","key":"10.1016\/j.neuropharm.2021.108555_bib257","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/glia.20532","article-title":"Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein","volume":"55","author":"Zhang","year":"2007","journal-title":"Glia"},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108555_bib258","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1096\/fj.04-2751com","article-title":"Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease","volume":"19","author":"Zhang","year":"2005","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2021.108555_bib259","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fnana.2017.00077","article-title":"Microglia polarization with M1\/M2 phenotype changes in rd1 mouse model of retinal degeneration","volume":"11","author":"Zhou","year":"2017","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.neuropharm.2021.108555_bib260","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2147\/NDT.S7788","article-title":"Current and emerging treatments for amyotrophic lateral sclerosis","volume":"5","author":"Zoccolella","year":"2009","journal-title":"Neuropsychiatric Dis. Treat."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082100109X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082100109X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:56:43Z","timestamp":1762214203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082100109X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":260,"alternative-id":["S002839082100109X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108555","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cannabinoid system and microglia in health and disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108555"}}